Research in cancer immunology at the Sidney Kimmel Comprehensive Cancer Center (SKCCC), Johns Hopkins University (JHU) has undergone a natural progression from basic laboratory studies of the host immune response to cancer to the clinical evaluation of immune-based cancer therapies. Many of these immune-based strategies to mobilize and augment the anti-tumor immune response were founded on the discoveries made by JHU investigators. Moreover, the application of immunotherapeutic strategies as an adjunct to cancer treatment across a wide range of malignancies and therapeutic settings has expanded dramatically over the past several years. The ability to carefully and reliably quantify the human immune response is critically important to assess the impact of any immunotherapeutic strategy. While there is great diversity in the therapeutic modalities being studied, most areas, in fact, overlap strongly in their techniques and approaches to immunological analysis. Modern immunological techniques for characterizing and quantifying human immune responses are complex, and it is difficult for individual investigators to assemble all the techniques that may be most appropriate for a particular project. The Human Immunology Core Laboratory (HICL) was established in 2005 to provide SKCCC investigators the capacity to reliably monitor and quantify human immune responses using state-of-the-art immunologic assays. Thus, the specific goals of this CORE are to: 1) Provide technical expertise and conduct immunological assays to monitor and characterize the human immune responses;2) Establish standard operating procedures and quality control measures for all immunological assays;3) Communicate its expertise and availability to SKCCC investigators;4) Provide technical support to SKCCC investigators seeking to identify and develop assays specific to their research objectives, and 5) Serve as a repository for key reagents and cell lines useful for the study of human immunology. Taken together, the HICL plays an important role in monitoring human immune responses that crosses many disciplines within the SKCCC and provides for the development of new therapeutic approaches to augment the anti-tumor immune response. Lay: The Human Immunology Core Laboratory identifies different subsets of lymphocytes that participate in the immune response to cancer and assesses their function and their ability to produce inflammatory cytokines that amplify the immune response. By tracking or monitoring the immune response, the Human Immunology Core Laboratory can assist investigators assess the impact or influence of their therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-51
Application #
8661014
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-05-01
Budget End
2015-04-30
Support Year
51
Fiscal Year
2014
Total Cost
$70,761
Indirect Cost
$27,170
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Taube, Janis M; Galon, Jérôme; Sholl, Lynette M et al. (2018) Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol 31:214-234
Giraldo, Nicolas A; Nguyen, Peter; Engle, Elizabeth L et al. (2018) Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab. J Immunother Cancer 6:99
Barberi, Theresa; Martin, Allison; Suresh, Rahul et al. (2018) Absence of host NF-?B p50 induces murine glioblastoma tumor regression, increases survival, and decreases T-cell induction of tumor-associated macrophage M2 polarization. Cancer Immunol Immunother 67:1491-1503
Dean, Lorraine T; Gehlert, Sarah; Neuhouser, Marian L et al. (2018) Social factors matter in cancer risk and survivorship. Cancer Causes Control 29:611-618
Krueger, Timothy E G; Thorek, Daniel L J; Denmeade, Samuel R et al. (2018) Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise. Stem Cells Transl Med 7:651-663
Boudadi, Karim; Suzman, Daniel L; Anagnostou, Valsamo et al. (2018) Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. Oncotarget 9:28561-28571
Annesley, Colleen E; Rabik, Cara; Duffield, Amy S et al. (2018) Knock-in of the Wt1 R394W mutation causes MDS and cooperates with Flt3/ITD to drive aggressive myeloid neoplasms in mice. Oncotarget 9:35313-35326
Yuan, Ming; Da Silva, Ana Cristina A L; Arnold, Antje et al. (2018) MicroRNA (miR) 125b regulates cell growth and invasion in pediatric low grade glioma. Sci Rep 8:12506
Jacobs, Michael A; Macura, Katarzyna J; Zaheer, Atif et al. (2018) Multiparametric Whole-body MRI with Diffusion-weighted Imaging and ADC Mapping for the Identification of Visceral and Osseous Metastases From Solid Tumors. Acad Radiol 25:1405-1414
Ramos, Juan C; Sparano, Joseph A; Rudek, Michelle A et al. (2018) Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075). Clin Lymphoma Myeloma Leuk 18:180-190.e2

Showing the most recent 10 out of 2393 publications